Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Date:1/26/2009

rally inhaled acute migraine medication in development which has a multi-targeted mechanism of action, utilizes the company's proprietary TEMPO(R) inhaler and is designed to optimize the key characteristics of dihydroergotamine, an active ingredient which has been used to effectively and safely treat migraines for over 60 years. MAP0004 has the potential to provide a faster onset of action than currently available migraine treatments, with sustained pain relief and pain freedom, in an easy-to-use, non-invasive, at-home therapy. In a Phase 2 clinical trial, patients reported pain relief in as fast as 10 minutes, with sustained relief to 24 and 48 hours. The safety data generated to date have shown MAP0004 to be well tolerated with no significant adverse events reported.

Migraine is a common, debilitating neurological disease affecting approximately 30 million people in the United States, according to the National Headache Foundation (NHF). Common symptoms include recurrent attacks of headaches, nausea, vomiting and sensitivity to light and sound. According to the NHF, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technolo
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... , July 1, 2015 Isagenix International, a ... earned three Gold, three Silver, and three Bronze Stevie® ... held in Chicago this month.The ... premier business awards program in the U.S. ... company,s strength in developing leaders, cultivating talent, creating a ...
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... Kan., Feb. 28 Aided by the Kansas,Bioscience ... go national,with specialized training programs that will keep ... continue enjoying the benefits of,cutting-edge, world-class research to ... have grown significantly in recent,years, leading to unprecedented ...
... BCRX ) today announced that its fourth quarter ... Tuesday, March 4,2008. At 8:30 a.m. Eastern Time BioCryst ... financial results and provide an update on the,Company,s programs ... by Jon,P. Stonehouse, BioCryst,s Chief Executive Officer, and Stuart ...
... of biotech contract service providers, INDIANAPOLIS, ... the life sciences, has released an extensive ... biotechnology industries,holding significant promise for Indiana,s continued ... launched a new Web site --, http://www.biocrossroadslinx.com ...
Cached Biology Technology:K-State Preparing to Share Expertise With Bioscientists 2BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008 2BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008 3BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services 2BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services 3BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services 4
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... is the target of potent antibiotics such as penicillin ... of carbohydrate chains, linked together by peptides, which wrap ... according to research conducted by scientists at the California ... cell-wall structure in three dimensions was made possible by ...
... mentally, but genetically everyone is very similar. That,s ... But with population research becoming more and more ... concerned that genetic research could awaken racist attitudes. ... geneticist James Watson claimed there are genes responsible ...
... The International Commission for the Conservation of Atlantic ... Marrakech, Morocco to make decisions on measures to save ... this year with mounting evidence of the impending collapse, ... Mediterranean bluefin tuna fishery is an "international disgrace" and ...
Cached Biology News:Caltech researchers get first 3-D glimpse of bacterial cell-wall architecture 2Could genetic research awaken racist attitudes? 2Tuna Commission to decide the future of Mediterranean bluefin 2
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
... Sepharose 4B, 10 ... purification of calmodulin-binding ... of calmodulin-regulated proteins ... cells. Category: Chromatography ...
Biology Products: